LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.34 -4.29

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.31

Máximo

1.42

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+89.36% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-21M 81M
Apertura anterior	5.63
Cierre anterior	1.34

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 mar 2026, 23:12 UTC

Acciones populares

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mar 2026, 22:15 UTC

Ganancias

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mar 2026, 21:42 UTC

Noticias de Eventos Importantes

Stryker Says Cyberattack Disruption Is Continuing

12 mar 2026, 21:29 UTC

Noticias de Eventos Importantes

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mar 2026, 21:27 UTC

Ganancias

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mar 2026, 20:46 UTC

Ganancias

Adobe Posts Higher Sales With CEO Set to Depart

12 mar 2026, 20:21 UTC

Noticias de Eventos Importantes

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mar 2026, 23:57 UTC

Charlas de Mercado

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mar 2026, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 mar 2026, 23:38 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mar 2026, 22:13 UTC

Ganancias

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mar 2026, 22:13 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

12 mar 2026, 22:13 UTC

Charlas de Mercado

Ganancias

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mar 2026, 21:16 UTC

Adquisiciones, fusiones, absorciones

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mar 2026, 21:04 UTC

Ganancias

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mar 2026, 21:02 UTC

Ganancias

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mar 2026, 20:57 UTC

Charlas de Mercado

Noticias de Eventos Importantes

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

12 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mar 2026, 20:10 UTC

Ganancias

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mar 2026, 20:05 UTC

Ganancias

Adobe 1Q Rev $6.4B >ADBE

12 mar 2026, 20:05 UTC

Ganancias

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

89.36% repunte

Estimación a 12 Meses

Media 2.67 USD 89.36%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.